Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1883Lung Neoplasms 1308Small Cell Lung Carcinoma 329Colorectal Neoplasms 271Breast Neoplasms 243Melanoma 221Neoplasms 218Ovarian Neoplasms 193Neoplasm Metastasis 181Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 152Stomach Neoplasms 143Head and Neck Neoplasms 120Carcinoma, Renal Cell 119Triple Negative Breast Neoplasms 111Esophageal Neoplasms 109Prostatic Neoplasms 107Endometrial Neoplasms 98Uterine Cervical Neoplasms 97Urinary Bladder Neoplasms 89Mesothelioma 88Colonic Neoplasms 86Mesothelioma, Malignant 81Carcinoma, Hepatocellular 74Brain Neoplasms 70Sarcoma 64Disease 63Adenocarcinoma of Lung 60Carcinoma, Transitional Cell 54Liver Neoplasms 49

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ALK Positive Non-small Cell Lung Cancer × Thoracic × 1 year × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡